KŘÍŽKOVÁ, Soňa, Markéta RYVOLOVÁ, Jaromír GUMULEC, Michal MASAŘÍK, Vojtěch ADAM, Petr MAJZLÍK, Jaromír HUBÁLEK, Ivo PROVAZNÍK and René KIZEK. Electrophoretic fingerprint metallothionein analysis as a potential prostate cancer biomarker. Electrophoresis. 2011, vol. 32, No 15, p. 1952–1961. ISSN 0173-0835. Available from: https://dx.doi.org/10.1002/elps.201000519.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Electrophoretic fingerprint metallothionein analysis as a potential prostate cancer biomarker
Authors KŘÍŽKOVÁ, Soňa (203 Czech Republic), Markéta RYVOLOVÁ (203 Czech Republic), Jaromír GUMULEC (203 Czech Republic, belonging to the institution), Michal MASAŘÍK (203 Czech Republic, belonging to the institution), Vojtěch ADAM (203 Czech Republic), Petr MAJZLÍK (203 Czech Republic), Jaromír HUBÁLEK (203 Czech Republic), Ivo PROVAZNÍK (203 Czech Republic) and René KIZEK (203 Czech Republic, guarantor).
Edition Electrophoresis, 2011, 0173-0835.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10600 1.6 Biological sciences
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.303
RIV identification code RIV/00216224:14110/11:00049977
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1002/elps.201000519
UT WoS 000294179800005
Keywords in English Blood marker Glutathione Metallothionein Prostate cancer Prostatespecific antigen
Tags International impact
Changed by Changed by: Mgr. Michal Petr, učo 65024. Changed: 12/4/2012 07:32.
Abstract
Prostate-specific antigen (PSA) is a routinely used marker of prostate cancer; however, the cut-off values for unambiguous positive/negative prostate cancer diagnoses are not defined. Therefore, despite the best effort, certain percentage of misdiagnosed cases is being recorded every year. For this reason, search formore specific diagnosticmarkers is of great interest. In this study, systematic comparison of PSA and metallothionein (MT) levels in blood serum of 46 prostate cancer-diagnosed patients is presented. It is clearly demonstrated that PSA levels vary significantly and despite normal total PSA values in the range of 0 – 4 ng/mL were obtained in over 36.9% of cases, positive prostate cancer was diagnosed by biopsy. In contrary, MT levels were considerably elevated in all tested samples and no significant variations were observed. These results are indicating the potential of MT as an additional prostate cancer marker reducing, in combination with PSA, the probability of false positive/negative diagnosis. To increase the throughput of the screening, chip-based capillary electrophoresis was suggested as a rapid and effective method for the fingerprinting analysis of prostate cancer from diseased blood sera.
Links
GA102/07/1473, research and development projectName: Optické metody registrace elektrických potenciálů a koncentrace vápníku v srdci s laserovou stabilizací
Investor: Czech Science Foundation
GD204/08/H054, research and development projectName: Molekulární mechanismy proliferace a diferenciace buněk
Investor: Czech Science Foundation, Molecular mechanisms of the cell proliferation and differentiation
GP301/09/P436, research and development projectName: Analýza metalothioneinu u karcinomu prostaty na úrovni DNA, RNA a proteinu.
Investor: Czech Science Foundation
NS10200, research and development projectName: Nádorové markery, jejich stanovení a korelace s karcinomem prostaty
Investor: Ministry of Health of the CR
PrintDisplayed: 8/10/2024 14:23